Whole-body and single-photon emission computed tomography/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-tetraazacyclododecanetetraacetic Acid–Octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases
KoramadaiKaruppusamy Kamaleshwaran, Malipedda Suneelkumar, Raghunathan Madhusairam, EdathuruthyKalarikal Radhakrishnan, Soundararajan Arunpandiyan, VasumathiJayaraj Arnold
Abstract
Somatostatin receptor-targeted alpha radionuclide therapies have been introduced including actinium-225 labeled tetraazacyclododecanetetraacetic acid-octreotide (Ac-225 DOTATATE) for advanced metastatic neuroendocrine tumors (NET). Very limited data are available on the posttherapy imaging using Ac-225 DOTATATE therapy in metastatic NET. We present Ac-225 single-photon emission computed tomography/computed tomography images of a 72-year-old patient diagnosed as a case of advanced rectal NET treated primarily with Ac-225 DOTATATE.
Topics & Concepts
MedicineRadionuclide therapyNeuroendocrine tumorsSomatostatin receptorOctreotideNuclear medicineSingle-photon emission computed tomographyRadiologyEmission computed tomographyComputed tomographyPositron Emission Tomography-Computed TomographyPET-CTPositron emission tomographySomatostatinInternal medicineNeuroendocrine Tumor Research AdvancesNeuroblastoma Research and TreatmentsLung Cancer Research Studies